Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
Author:
Funder
University of Fribourg
University of Geneva
Swiss National Science Foundation
Publisher
Elsevier BV
Subject
Pharmacology
Reference61 articles.
1. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018
2. Emerging concepts for immune checkpoint blockade-based combination therapies;Zappasodi;Cancer Cell,2018
3. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study;Ribas;Cancer Discov.,2018
4. Trial Watch: toll-like receptor agonists in cancer immunotherapy;Smith;Oncoimmunology,2018
5. Translating nucleic acid-sensing pathways into therapies;Junt;Nat. Rev. Immunol.,2015
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. GSDMD is associated with survival in human breast cancer but does not impact anti-tumor immunity in a mouse breast cancer model;Frontiers in Immunology;2024-08-19
2. High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects;Journal of Medical Virology;2024-05-24
3. Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings;PLOS ONE;2024-05-22
4. Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities;Clinical and Translational Medicine;2024-04
5. Harnessing innate immune pathways for therapeutic advancement in cancer;Signal Transduction and Targeted Therapy;2024-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3